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Polymorphisms in NOD2 represent the single greatest genetic risk factor for the
development of Crohn’s disease. Three different non-synonomous NOD2 polymor-
phisms – R702W, G908R, and L1007fsincC – account for roughly 80% of all NOD2-
associated cases of Crohn’s disease and are reported to result in a loss of receptor
function in response to muramyl dipeptide (MDP) stimulation. Loss of NOD2 signaling
can result from a failure to detect ligand; alterations in cellular localization; and changes
in protein interactions, such as an inability to interact with the downstream adaptor
protein RIPK2. Using an overexpression system, we analyzed ~50 NOD2 polymorphisms
reportedly connected to Crohn’s disease to determine if they also displayed loss of
function and if this could be related to alterations in protein localization and/or association
with RIPK2. Just under half the polymorphisms displayed a significant reduction in
signaling capacity following ligand stimulation, with nine of them showing near complete
ablation. Only two polymorphisms, R38M and R138Q, lost the ability to interact with
RIPK2. However, both these polymorphisms still associated with cellular membranes. In
contrast, L248R, W355stop, L550V, N825K, L1007fsinC, L1007P, and R1019stop still
bound RIPK2, but showed impaired membrane association and were unable to signal
in response to MDP. This highlights the complex contributions of NOD2 polymorphisms
to Crohn’s disease and reiterates the importance of both RIPK2 binding and membrane
association in NOD2 signaling. Simply ascertaining whether or not NOD2 polymorphisms
bind RIPK2 or associate with cellular membranes is not sufficient for determining their
signaling competency.
Keywords: Crohn’s disease, inflammation, innate immunity, NLR, NFκB, signal transduction, membrane
localization, RIP2
Abbreviations: CARD, caspase activation domain; LRR, leucine-rich repeat; MDP, muramyl dipeptide; NFκB, nuclear
factor κB; NOD2, nucleotide oligomerization domain 2; RIPK2, receptor-interacting serine/threonine kinase 2; SNP, single
nucleotide polymorphism.
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INTRODUCTION
Nucleotide oligomerization domain 2 (NOD2) is a cytoplas-
mic pattern recognition receptor that has been connected with
a variety of inflammatory disorders including Crohn’s disease,
Blau syndrome, asthma, sarcoidosis, and arthritis (1). NOD2
is organized into three primary functional domains: an N-
terminal effector region consisting of two caspase activation
domains (CARDs); a central nucleotide-binding domain; and
a C-terminal series of leucine-rich repeats (LRRs). NOD2 is
maintained in an inactive state in the cell by interactions with
chaperones, such as HSP90 and SGT1 (2, 3). However, detection
of muramyl dipeptide (MDP), a component of bacterial pep-
tidoglycan, along with binding and hydrolysis of ATP initiates
receptor activation. Formation of the active signaling complex,
most likely occurs at cellular membranes and signal propagation
requires interaction with specific adaptor proteins. This primar-
ily involves CARD-mediated interaction with the adaptor kinase
receptor-interacting protein kinase 2 (RIPK2), but other proteins,
such as CARD9 and TRAF4, can also be involved. This stim-
ulates a pro-inflammatory immune response via nuclear factor
kappa B (NFκB) and mitogen-associated protein kinase (MAPK)
pathways.
Crohn’s disease is a chronic inflammatory bowel disorder in
which intestinal immune responses, most commonly in the ileum
and colon, become dysregulated. The etiology of Crohn’s disease
is complex and whilst the precise cause, or causes, is uncertain, it
is clear that genetic factors are an important contributory com-
ponent to disease progression. Of the more than 70 genes asso-
ciated with Crohn’s disease, polymorphisms in NOD2 remain the
single greatest genetic risk factor (4, 5). Three non-synonomous
polymorphisms – R702W, G908R, and L1007fsincC – account
for around 80% of all NOD2-polymorphism associated cases of
Crohn’s disease reported, with homozygotic mutation resulting
in around a 10-fold greater risk than heterozygotic mutation.
Somewhat counter-intuitively all three of the major NOD2 poly-
morphisms associated with Crohn’s disease result in a loss of
receptor function and reduced inflammatory signaling (6, 7).
The reduction in NOD2 function has, however, been proposed
to contribute to disease via a number of different mechanisms
that includes: disruption of the host microbiota, dysregulation
of intestinal tolerance, and enhanced activation of other pro-
inflammatory signaling pathways (8–11). The precise contri-
bution of these mechanisms to disease pathogenesis, however,
remains enigmatic.
Genetic studies have reported numerous other polymorphisms
inNOD2 that associate with Crohn’s disease.Wewere interested in
seeing whether these polymorphisms also displayed a loss of func-
tion in response to ligand stimulation, and in identifying whether
or not dysfunction could be related to disruption of RIPK2 bind-
ing and/or membrane association. We generated over 50 NOD2
constructs containing these polymorphisms and assessed their
response to ligand stimulation. Twenty-three variants showed
a significant reduction in signaling capacity with nine of them
(R38M, R138Q, L248R, W355stop, L550V, E825K, L1007fsinC,
L1007P, and R1019stop) showing a near complete loss of signaling
capacity. Whilst no single cause for the loss of function could be
identified, both RIPK2 binding and membrane association were
important factors. Overall our data is consistent with the view
that Crohn’s disease-associated NOD2 polymorphisms result in
receptor dysfunction, but that the causes of this dysfunction are
multi-factorial.
MATERIALS AND METHODS
Chemicals, Plasmids, Antibodies, and
General Methods
Chemical reagents were obtained from Sigma-Aldrich, UK, unless
otherwise specified. HEK293T and HeLa cells were maintained
in DMEM supplemented with 10% fetal calf serum, 100μg/ml
penicillin/streptomycin and 2mM -glutamine at 37°C and 5%
CO2. All transfections were performed using jetPEI™(Polyplus-
Transfection) as per the manufacturers’ instructions. pCMV-
FLAG-NOD2, encoding N-terminally FLAG-tagged full length
NOD2; pCI-myc-RIPK2, encoding N-terminally myc-tagged full
length RIPK2; and pEF6-V5-mCARD9, encoding N-terminally
V5-tagged full length murine CARD9 were kind gifts from Pro-
fessors Thomas Kufer (12), Kate Fitzgerald, and David Under-
hill, respectively. Crohn’s disease-associated single nucleotide
polymorphisms (SNPs) were identified using published litera-
ture (5, 6, 13–18) and the NCBI SNP database and generated
using site directed mutagenesis. Mutant sequences were ver-
ified by DNA sequencing of the entire open reading frame.
Plasmids encoding Firefly luciferase under the control of an
NFκB (pluc) or IL-8 promoter (pluc-IL8) and Renilla luciferase
controlled by a constitutive promoter (phrG) were kind gifts
from Prof Clare Bryant. Antibodies used in this work were
rabbit anti-FLAG (F7425, Sigma-Aldrich), mouse anti-FLAG
M2 (F3165, Sigma-Aldrich), mouse anti-V5 (ab27671; Abcam),
mouse anti-GAPDH (ab9485, Abcam), rabbit anti-Myc (ab9106,
Abcam), goat anti-rabbit (ab6721, Abcam), goat anti-mouse
(A4416, Sigma-Aldrich), Alexa-488 goat anti-mouse (A11001,
Life Technologies), and Alexa-555 goat anti-rabbit (A21428, Life
Technologies).
HEK293 Reporter Assays
HEK293T cells in 96-well plateswere transfectedwith 2 ng pLuc or
pLuc-IL-8, 1 ng phrG, 0.1 ng wild-type or mutant pCMV-FLAG-
NOD2, and made up to 0.1μg total DNA with empty plasmid.
One hundred nanograms per milliliter MDP (Invivogen) was
added concomitant with transfection. Cells were lysed 24 h post-
transfection with 1 passive lysis buffer (Promega) and lumines-
cence measured with a LUMIstar Luminometer (BMG Labtech).
Each SNP was tested in triplicate in a minimum of three separate
experiments. Reporter assays routinely show variations between
experiments as a result of differences in transfection efficiency and
cell passage number. In order to allow comparison between exper-
iments, data was normalized to the signal obtained using wild-
type NOD2 and expressed as a percentage of wild-type signaling
activity.
Data was plotted and analyzed with GraphPad Prism 5. To
correct for unequal variance, data was log transformed, then sub-
jected to statistical analysis using a one-way analysis of variance
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with a Bonferroni multiple comparison post hoc test. Data are
expressed as mean+ SEM and a p-value of <0.05 was taken as
significant.
Immunoprecipitation
HEK293T cells seeded in 6-well plates (Costar) were transfected
with 1μg of the appropriate pCMV-FLAG-NOD2 construct and
0.5μg pCI-myc-RIP2 and incubated overnight. Cells were lysed
and incubated with Dynabeads (Life Technologies) labeled with
mouse anti-FLAG (Sigma) as per the manufacturers’ instructions.
Samples were denatured by the addition of SDS-loading buffer
(Invivogen) and heating for 5min at 90°C prior to separation by
SDS-PAGE using 4–20%Tris-glycine gels (NuSep) for 1 h at 200V.
Proteins were transferred to polyvinylidene fluoride membranes
for detection by Western Blot using the appropriate antibodies.
Immunofluorescence
HeLa cells were seeded into 12-well plates containing a sterilized
19-mmdiameter glass coverslip. Cells were transfected either with
1μg of wild-type or mutant pCMV-FLAG-NOD2, or with 0.5μg
of each of the appropriate constructs for co-immunofluorescence
studies. Cells were incubated overnight before washing (1 PBS)
and fixing for 15min (4% paraformaldehyde in PBS). Cells
were washed again (1 PBS), permeabilized [0.4% Triton X-100
(VWR) in 1 PBS] for 10min, blocked for 20min (2.5% goat
serum, 1% bovine serum albumin in 1 PBS), then incubated
with appropriate primary and secondary antibodies. Cells were
subsequently washed three times with 1 PBS, the second wash
containing a 1:5000 dilution of 10mg/ml Hoechst 33258 in PBS
to stain the nucleus. Coverslips were mounted onto microscope
slides (VWR) using Mowiol mounting solution containing 2.5%
1,4-diazabicyclo[2.2.2]octane to reduce fading. Cells were visu-
alized using an AXIO Imager.M2 microscope (Carl Zeiss Ltd.,
Cambridge, UK) and images created using Image J.
Subcellular Fractionation
This was performed using a Subcellular Protein Fractionation Kit
(Perbio Science UK) as per the manufacturers’ instructions from
HEK293T cells overexpressing the appropriate NOD2 mutant
constructs and grown in 12-well plates. Cytosolic and membrane
fractions were isolated and analyzed by SDS-PAGE and western
blotting. The proportion of NOD2 associated with the membrane
was calculated by densitometry using Image J (19).
Bioinformatics
Full length human NOD2 (NP_071445.1) was used to search the
non-redundant protein database at NCBI. Recovered sequences
with at least 90% coverage of human NOD2 were retained and
manually curated to remove proteins that were described as pre-
dicted or hypothetical, or which were clear species duplications.
In the latter circumstance, the protein with the highest scoring
alignment for that species was retained. In total, NOD2 sequences
from 30 different species were subsequently submitted for mul-
tiple sequence alignment using MUSCLE (20). Accession codes
are detailed in Figure S2 in Supplementary Material. Homology
models of the NOD2 CARDS were generated using the NOD1
CARD [PDB 2DBD] as a template.
RESULTS
Selection of NOD2 Single Nucleotide
Polymorphisms for Study
At the outset of this study, 98 SNPs in NOD2 associated
with either Blau Syndrome or Crohn’s disease were identified
using published data (5, 6, 13–18) and the NCBI database
of NOD2 SNPs (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?
locusId=64127). The Blau Syndrome-associated polymorphisms
were studied, and have been reported, independently of those
associated with Crohn’s disease (21). Seventeen SNPs previously
shown to have an NFκB activity comparable to wild-type NOD2
(6)were excluded from further study, aswere three SNPs forwhich
alternative polymorphisms existed at the residue of interest. Nine
polymorphisms could not be successfully generated in the NOD2
expression vector. In total, 53 Crohn’s disease-associated poly-
morphisms were taken forward for functional characterization
in conjunction with wild-type NOD2 and the inactive Walker-B
mutant D379A as control constructs.
Crohn’s Disease-Associated NOD2
Polymorphisms can Result in a Defective
Response to MDP Stimulation
To determine the effect of the NOD2 polymorphisms on recep-
tor function, we assessed their ability to signal in response to
MDP stimulation using NFκB and IL-8 reporter assays. Twenty-
three of the polymorphisms, along with the Walker-B mutant
D379A, showed a significant reduction in signaling (Figure 1).
All polymorphisms that showed a significant reduction in sig-
naling activity with the exception of A105T, D113N, D357A
(IL-8 only), and P727C (NFκB only) were significantly impaired
in both reporter systems. Nine of the polymorphisms (R38M,
R138Q, L248R, W355stop, L550V, N825K, L1007fs, L1007P,
and R1019stop) and the control D379A showed major func-
tional impairment with signaling below 15% of wild-type NOD2
(Figure 1). None of the polymorphisms tested resulted in receptor
hyperactivation in response to MDP (Figure S1 in Supplementary
Material).
Amino Acid Conservation can be Indicative
but does not Correlate with Functional
Impact
Amino acids with important functional roles regularly show
higher levels of evolutionary conservation. We updated our pre-
vious cross-species alignment of NOD2 (22) and compared the
level of evolutionary conservation for each of our polymorphic
NOD2 variants (Figure 2; Figures S1 and S2 in Supplementary
Material). Consistent with a key functional role, nine of the poly-
morphisms that showed a significant reduction in signaling were
completely conserved across all aligned species, and a further two
(E825 and L1007) were conserved in 29/30 species (Figure 2).
However, high levels of residue conservation could not be used
as a direct predictor of functional impact as seven completely
conserved residues showed no impact on signaling (Figure 2A).
Interestingly, V162 is only conserved in five of the 30 species and
despite all of the substitutions being conservative hydrophobic
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FIGURE 1 | Twenty-three NOD2 polymorphisms show a significant reduction in signaling following stimulation with MDP. The ability of NOD2
polymorphisms to signal via NFκB (black bars) or activate the IL-8 promoter (blue bars) was determined following stimulation with 100 ng/ml MDP. Signaling
functionality is expressed as a percentage of wild-type receptor activity. All polymorphisms were tested in triplicate in a minimum of three separate experiments. Error
bars show SEM. Data was log transformed and statistical significance determined using one-way ANOVA with Bonferroni post-test for multiple samples. Only
polymorphisms showing a significant reduction in signaling are plotted (data for the other polymorphisms is provided in Figure S1 in Supplementary
Material) – *p<0.05, **p=<0.01, ***p=<0.001. A schematic of the NOD2 domain structure is provided with the location of polymorphisms showing <15%
activity marked.
ones, the polymorphism V162I signals at <25% of the wild-type
protein (Figures 1 and 2B). In fact 10 species, including members
of the bovine, porcine, caprine, and canine families, all possess
an isoleucine in this position and therefore may show impaired
NOD2 functionality.
RIPK2 Binding is not Sufficient for
NOD2 Signaling
Following activation of NOD2, signal propagation requires inter-
action with the adaptor protein RIPK2 in a CARD-dependent
manner. To determine if NOD2 SNPs with a signaling defect were
impaired in their ability to interact with RIPK2 we performed co-
immunoprecipitations in HEK293T cells between FLAG-tagged
NOD2 constructs and Myc-tagged RIPK2. With the exception of
R38M and R138Q, all the tested NOD2 polymorphisms retained
the ability to bind RIPK2 (Figure 3A; Figure S1 in Supplemen-
tary Material), thereby indicating that whilst the interaction with
RIPK2 is necessary for signal transduction, it is not sufficient. This
is consistent with recent observations between NOD1 and RIPK2
(23). The inability of R38M and R138Q to interact with RIPK2
was confirmed by immunofluorescence inHeLa cells (Figure 3B).
Wild-type NOD2 showed membrane-based co-localization with
RIPK2 following overexpression. However, whilst both R38M
and R138Q still associated with the cell membrane they did not
localize with RIPK2 (Figure 3B). In fact, in the presence of R38M
and R138Q RIPK2 showed a punctate distribution in the cell inte-
rior (Figure 3B) that matched its distribution when transfected
into HeLa cells in the absence of NOD2 (Figure 3B). Homology
models of the NOD2 CARDs (Figures 3C,D) indicated that both
R38 and R138 are predicted to be located in equivalent positions
on the first helix of the first and second CARDs, respectively. This
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FIGURE 2 | The relationship between residue conservation and functional impact. (A) Scatter plot of percentage residue identity and percentage NFκB
signaling activity for all polymorphisms studied. Polymorphisms that cause a significant reduction in signaling are colored red and labeled. The points for R38M and
R138Q overlap on the graph. (B) WebLogo representation of residue conservation for those polymorphisms producing a significant reduction in signaling.
Polymorphism position is denoted on the x-axis and colored by level of NFκB signaling compared to WT NOD2 – red <15%, blue 15–45%, gray 46–75%, and black
>75%. Amino acid residues are colored as follows: basic residues – blue; acidic residues – red; hydrophobic residues – black; polar acidic residues – green; and
polar basic residues – pink.
strongly suggests that this region on both CARDs is crucial for the
interaction with RIPK2.
Association of NOD2 Polymorphisms
with Membranes does not Directly Relate
to Functionality
Our immunofluorescence of R38M and R138Q (Figure 3B) indi-
cated that these polymorphisms were still recruited to the mem-
brane despite being unable to signal. This suggested that whilst
the association of NOD2 with cellular membranes is impor-
tant for signal transduction, it does not in fact guarantee that
signaling will occur. To study whether the other dysfunctional
polymorphisms showed altered membrane association we per-
formed immunofluorescence and subcellular fractionation on a
collection of overexpressed polymorphisms displaying a range of
signaling activity (Figure 4). The extent of membrane association
was estimated by densitometry of the subcellular fractionation
data (Figure 4A). As shown by the scatter plot in Figure 4C,
no clear correlation between the degree of membrane association
and the extent of receptor signaling could be drawn. However,
polymorphisms associated with a significant reduction in sig-
naling could be assigned into three main groups. Those with a
membrane association and signaling activity below 15% (L248R,
D379A, N825K, L1007P, L1007fs, and R1019stop); those with
membrane association similar, or fractionally lower than wild-
type and low signaling activity (R38M, R138Q, V162I, W355stop,
P463A, and L550V); and those with slightly impaired signaling,
but similar or slightly low membrane association. With the excep-
tion of I363F none of the polymorphisms with <20% membrane
association signaled at levels above 15% of the wild-type receptor.
Analysis of a wider range of functional and dysfunctional NOD2
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FIGURE 3 | Impact of NOD2 polymorphisms on the interaction with RIPK2. (A) HEK293T cells seeded in 6-well plates were transiently transfected with 0.5μg
pCI-myc-RIP2 and 1μg pCMV-FLAG-NOD2 polymorphic constructs as labeled. After 24 h, cell lysates were immunoprecipitated using Dynabeads labeled with
mouse anti-FLAG antibody. Proteins were separated by SDS-PAGE and proteins detected using the antibodies specified. (B) Immunofluorescence was performed in
12-well plates using HeLa cells seeded onto coverslips using 0.5μg pCMV-FLAG-NOD2 or pCI-myc-RIP2 and the protein localization was visualized following
antibody staining (left panel). Co-localization studies were performed by transfecting 0.5μg of pCI-myc-RIP2 with 0.5μg of each of pCMV-FLAG-NOD2/
R38M/R138Q or pEF6-V5-CARD9 (right panel). Examples of membrane-associated fluorescence are indicated by arrows. The scale bar indicates 20μm. Cartoon
representation of homology models of the first (C) and second (D) CARDs of NOD2 showing the conserved location of R38 and R138 (red spheres) and the location
of other CARD located polymorphisms (light green). Helices are annotated as H1–H6.
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FIGURE 4 |Membrane association of NOD2 polymorphisms. (A) NOD2 polymorphisms were transiently transfected in HEK293 cells. After 24 h cells were
harvested and the membrane and cytoplasmic fractions separated using the Pierce Subcellular Fractionation Kit. Proteins were resolved using SDS-PAGE and NOD2
constructs detected with anti-FLAG antibody. Detection of GAPDH confirmed the relative purities of the membrane and cytoplasmic fractions. The proportion of
NOD2 associated with the membrane was estimated by densitometry using ImageJ. (B) Representative immunofluorescence images showing the cellular localization
of overexpressed NOD2 constructs in HeLa cells. One microgram of the relevant DNA was transfected into HeLa cells seeded into 12-well plates containing a
coverslip. After 24 h, cells were fixed using 4% PFA in PBS and permeabilized using 0.4% Triton X-100. Proteins were stained using mouse anti-FLAG primary
antibody (Sigma) and Alexa Fluor® 555 goat anti-rabbit secondary antibody (Life Technologies). Cells were visulaised using an AXIO Imager.M2 microscope (Zeiss)
and images created using Image J. Membrane localization is indicated by arrows and the scale bar equals 20μm. (C) Scatter plot of percentage membrane
association plotted against percentage NFκB signaling activity. Polymorphisms that showed a significant reduction in signaling are colored red and labeled. The
wild-type receptor is represented as a purple square and labeled.
polymorphisms is needed before it can be determined whether
this is a strict correlation. The association of R38M, R138Q, and
W355stop at levels broadly similar to wild-type NOD2 suggest
that whilst membrane association is likely to play an important
role in NOD2 signaling, it is not sufficient for signal transduction
to occur.
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DISCUSSION
The etiology of Crohn’s disease is complex and is influenced
by combinations of genetic, lifestyle, and environmental fac-
tors. Polymorphisms in NOD2 present the strongest genetic sus-
ceptibility factor although over 70 separate genes have been
reported to be associated with the risk of disease develop-
ment and progression (4). Our understanding of how NOD2
SNPs predispose to Crohn’s disease is improving and in gen-
eral, they appear to result in defective NOD2 function (10).
However, the extent and severity of this defect is variable and
appears to show an element of cell-type and/or stimuli speci-
ficity. In this work, we have analyzed 53 Crohn’s disease-
associated SNPs for their effect on three key functional conse-
quences of NOD2 stimulation, namely: basal and ligand-induced
NFκB-driven signaling, interaction with RIPK2, and membrane
localization. Due to the low population frequency of the SNPs
studied, we employed an overexpression system, which despite
their acknowledged shortcomings, still provide a valuable system
for understanding the functional impact of mutations on protein
function.
It is clear from our results, and in agreement with the work of
other researchers investigating different NOD2 polymorphisms,
that not all Crohn’s disease-associated NOD2 polymorphisms
result in the same degree of functional impact. Indeed, only
23 of the SNPs we tested showed significant functional impair-
ment. This may reflect the presence of subtle functional impacts
that are masked by protein overexpression; that the polymor-
phisms affect functions not tested here, such as signaling via
CARD9; or that their reported association with Crohn’s dis-
ease is artifactual. These are all elements that require further
study.
Earlier studies have implicated R38, following mutation to
alanine, as important for the interaction of NOD2 and RIPK2
(24). Our observations, in which R38M and R138Q were the
only polymorphisms to lose the ability to efficiently interact
with RIPK2, are consistent with this assertion and also suggest
a crucial role in RIPK2 binding for R138Q. Homology models
show that R38 and R138 occupy equivalent position in the first
helix of the first and second CARDs, respectively (Figures 3C,D)
in a region that forms part of a basic patch on the surface
of each CARD. We observed dramatic reductions in signal-
ing capacity for R38M and R138Q, with the latter observation
consistent with earlier work (6). That other signaling defective
NOD2 polymorphisms retain the ability to interact with RIPK2
is consistent with our recent observations between NOD1 and
RIPK2 (23) and confirms that for both NOD1 and NOD2, the
engagement of RIPK2 is necessary, but not sufficient for signal
propagation.
It has been widely reported that membrane association is
an integral requirement for NOD2 signaling (17, 25–27). Our
observations in this work suggest that the connection between
NOD2 signaling and membrane association requires further clar-
ification. Five polymorphisms (L248R, N825K, L1007P, L1007fs,
and R1019stop) plus the Walker-B mutant (D379A) showed
minimal capacity to signal following ligand stimulation and
had very low levels of membrane association. Whilst I363F
despite showing <10% membrane association, still signaled at
around half the level of wild-type protein. In contrast, other
polymorphisms showed low (V162I and P463A) or very low
(R38M, R138Q, W355stop, and L550V) levels of activity, but
have levels of membrane association little different to wild-type
NOD2. In the case of R38M and R138Q, the lack of signal-
ing clearly relates to their failure to recruit RIPK2. However,
V162I, W355stop, P463A, and L550V all associate with mem-
brane and all engage RIPK2, but are still heavily impaired in
their signaling capacity, suggesting that the reasons for NOD2
dysfunction in these cases are somewhat more complex and
elusive.
Although residue conservation does not provide a clear and
definitive correlation with the functional impact of the polymor-
phisms, it can help rationalize why certain residues do, or do
not, have functional consequence when mutated. For example,
amino acids that showed high levels of evolutionary variation,
such as W157, R235, R708, and R760, generally showed limited
impairment in signaling. Whereas, the functional impact of poly-
morphic changes at highly conserved residue locations, such as
R38, R138, L248, and L1007, was much more dramatic. In some
instances, the reason for the dramatic impact and hence evolu-
tionary conservation are clear. For example, R38 and R138 are
needed for interaction with RIPK2; N825 forms part of the LRR
asparagine ladder and hence contributes to structural integrity;
and L1007 and R1019 are in the C-terminus of the protein and
important for membrane localization. On the other hand, why
L248 and L550 are completely conserved and functionally cru-
cial is less apparent. For L248, its importance may relate to its
proximity to CARD9 (28) and TRAF4 (29) binding sites and the
introduction of a large basic amino acid in the polymorphism
may disrupt these interactions. Similarly, mutation of L550 could
result in destabilization of the protein structure or interfere with
the interaction with chaperone proteins and hence disrupt the
transition from the inactive to active conformation of NOD2.
Reasons for the lack of functional impact for polymorphisms
of the other highly conserved residues are less clear, but in at
least the case of N852S, this reflects a change of residue that is
permitted in the structural context of that amino acid, i.e., serine
can functionally substitute for asparagines in the LRR asparagine
ladder (30).
Our work here provides one of the most detailed investiga-
tions into the functional impact of Crohn’s diseases-associated
polymorphisms. By assessing not just receptor signaling, but also
the interactionwith RIPK2, evolutionary conservation, and recep-
tor localization, we have provided an important insight into the
diverse range of functional impacts displayed by these polymor-
phisms. Importantly, the work highlights the benefit of studying
the functional impact of polymorphic variation through high-
lighting the complex relationship between NOD2 and its asso-
ciation with RIPK2 and cellular membranes in relation to signal
transduction.
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